Mostafid A Hugh, Rajkumar Raj G N, Stewart Alistair B, Singh Raj
Department of Urology, North Hampshire Hospital, Basingstoke, Hants, UK.
BJU Int. 2006 Mar;97(3):509-12. doi: 10.1111/j.1464-410X.2006.05965.x.
To assess the feasibility and safety of administering intravesical mitomycin C in theatre immediately after transurethral resection of bladder tumour (TURBT).
A protocol was developed to allow the safe administration of mitomycin C in theatre immediately after TURBT. Over a 32-month period all patients not excluded by the protocol were given mitomycin C in theatre after TURBT, and any adverse events reported.
In all, 177 instillations were carried out; there were two minor patient-related complications, and no staff-related adverse events.
The immediate administration of mitomycin C in theatre after TURBT is feasible and safe for patients and staff. It provides the earliest and surest prophylaxis against tumour cell re-implantation at TURBT.
评估经尿道膀胱肿瘤电切术（TURBT）后立即在手术室膀胱内灌注丝裂霉素C的可行性和安全性。
制定了一项方案，以确保在TURBT后立即在手术室安全地给予丝裂霉素C。在32个月的时间里，所有未被该方案排除的患者在TURBT后均在手术室接受了丝裂霉素C治疗，并报告了所有不良事件。
共进行了177次灌注；有两例与患者相关的轻微并发症，未发生与工作人员相关的不良事件。
TURBT后立即在手术室给予丝裂霉素C对患者和工作人员而言是可行且安全的。它为预防TURBT时肿瘤细胞再植入提供了最早且最可靠的措施。
